$3.20
At close: Apr 9, 11:48 AM EDT
Comments
Loading...
CanSino Biologics Analyst Ratings and Price Targets | OTC:CASBF | Benzinga
CanSino Biologics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for CanSino Biologics Corp from these most-recent analyst ratings.
Analyst Ratings for CanSino Biologics
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for CanSino Biologics (CASBF) stock?
There is no price target for CanSino Biologics
What is the most recent analyst rating for CanSino Biologics (CASBF)?
There is no analyst for CanSino Biologics
When was the last upgrade for CanSino Biologics (CASBF)?
There is no last upgrade for CanSino Biologics
When was the last downgrade for CanSino Biologics (CASBF)?
There is no last downgrade for CanSino Biologics.
When is the next analyst rating going to be posted or updated for CanSino Biologics (CASBF)?
There is no next analyst rating for CanSino Biologics.
Is the Analyst Rating CanSino Biologics (CASBF) correct?
There is no next analyst rating for CanSino Biologics.
Browse analyst ratings and price targets on all stocks.
